TY - JOUR
T1 - Expert Opinion on Diabetes Management Challenges and Role of Basal Insulin/GLP-1 RA Fixed-Ratio Combination in People with Type 2 Diabetes from Indonesia
AU - Suastika, Ketut
AU - Eliana, Fatimah
AU - Kshanti, Ida Ayu Made
AU - Mardianto, Mardianto
AU - Mudjarnako, Sony Wibisono
AU - Natalia, Nanny
AU - Heri Nugrohom, H. S.
AU - Sibarani, Roy Panusunan
AU - Soewondo, Pradana
AU - Soelistijo, Soebagijo Adi
AU - Tarigan, Tri Juli Edi
AU - Zufry, Hendra
N1 - Funding Information:
The Indonesian Society of Endocrinology provided financial support to the experts from the region across Indonesia who participated in the expert meeting and published the manuscript.
Publisher Copyright:
© 2022 Suastika et al.
PY - 2022
Y1 - 2022
N2 - Indonesia is struggling with a rapidly growing burden of diabetes due to rapid socioeconomic transition. People with type 2 diabetes mellitus (T2DM) need appropriate treatment strategies to maintain glycemic control. New modalities with simplicity, such as fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonist (GLP-1 RA), further referred to as FRC, have proven to be an effective and practical therapeutic approach that may address this issue. In January 2021, a scientific expert meeting was held with the participation of endocrinologists from Indonesia to provide expert opinions regarding the optimal practical use of the FRC basal insulin/GLP1-RA. Topics discussed in the meeting included the challenges in diabetes management, clinical inertia with insulin therapy, local and international guideline positioning, initiation, titration, and switching of basal insulin and GLP-1 RA, including FRC, and the management of T2DM.
AB - Indonesia is struggling with a rapidly growing burden of diabetes due to rapid socioeconomic transition. People with type 2 diabetes mellitus (T2DM) need appropriate treatment strategies to maintain glycemic control. New modalities with simplicity, such as fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonist (GLP-1 RA), further referred to as FRC, have proven to be an effective and practical therapeutic approach that may address this issue. In January 2021, a scientific expert meeting was held with the participation of endocrinologists from Indonesia to provide expert opinions regarding the optimal practical use of the FRC basal insulin/GLP1-RA. Topics discussed in the meeting included the challenges in diabetes management, clinical inertia with insulin therapy, local and international guideline positioning, initiation, titration, and switching of basal insulin and GLP-1 RA, including FRC, and the management of T2DM.
KW - basal insulin
KW - fixed-ratio combination
KW - GLP1 RA
KW - type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=85139094790&partnerID=8YFLogxK
U2 - 10.2147/DMSO.S367153
DO - 10.2147/DMSO.S367153
M3 - Article
AN - SCOPUS:85139094790
SN - 1178-7007
VL - 15
SP - 2977
EP - 2990
JO - Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
JF - Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
ER -
